Impact of anticholinergic medication use and risk of developing Alzheimer's Disease: A scoping review
DOI:
https://doi.org/10.33448/rsd-v13i10.47204Keywords:
Keywords, Cholinergic antagonists, Alzheimer disease, Dementia.Abstract
Most anticholinergic medications act through muscarinic receptors in the central nervous system, which can lead to a range of adverse effects, including neurodegenerative diseases such as dementia. This study aims to map the evidence available in the literature about the relationship between use of anticholinergics and development of Alzheimer's Disease. To this end, a scoping review was carried out following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) checklist. The searches were conducted in Biblioteca Virtual em Saúde (BVS), PubMed, Biblioteca Brasileira de Teses e Dissertações and ScienceDirect databases, considering only studies carried out in humans, without restrictions on publication date, geographic location or publisher. Editorial articles, correspondence, book chapters, book reviews, encyclopedias, errata, exams, mini reviews, news, short communications and conference abstracts were excluded. The selected studies were organized using Rayyan software, 68 articles were considered eligible for full reading and 13 were included in the final analysis. Among these, 4 studies didn't find an association between the use of anticholinergics and development of Alzheimer's disease. However, 9 studies reported a significant correlation between long-term use of anticholinergics and cognitive deterioration, suggesting an increased risk of developing dementia, including Alzheimer's disease. Therefore, evidence indicates a consistent association between long-term use of anticholinergic medications and increased risk of neurodegenerative diseases.
References
Arksey, H., & O’Malley, L. (2005). Scoping studies: towards a methodological framework. International Journal of Social Research Methodology, 8(1), 19–32. https://doi.org/10.1080/1364557032000119616.
Barker, A., Jones, R., Prior, J., & Wesnes, K. (1998). Scopolamine-induced cognitive impairment as a predictor of cognitive decline in healthy elderly volunteers: a 6-year follow-up. International journal of geriatric psychiatry, 13(4), 244-247.
https://doi.org/10.1002/(SICI)1099-1166(199804)13:4<244::AID-GPS764>3.0.CO;2-1.
Braun, A. E., Cowan, J. E., Hampson, L. A., Broering, J. M., Suskind, A. M., & Carroll, P. R. (2023). Association Between Common Urologic Medications and Onset of Alzheimer’s Disease and Related Dementias in Men With Prostate Cancer Managed by Different Primary Treatment Modalities. Urology, 182, 161–167. https://doi.org/10.1016/j.urology.2023.08.021.
Britt, D. M. I., & Day, G. S. (2016). Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults. Missouri Medicine, 113(3), 207–214. https://pmc.ncbi.nlm.nih.gov/articles/PMC5125613/
Chuang, Y.-F., Elango, P., Gonzalez, C. E., & Thambisetty, M. (2017). Midlife anticholinergic drug use, risk of Alzheimer’s disease, and brain atrophy in community-dwelling older adults. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 3(3), 471–479. https://doi.org/10.1016/j.trci.2017.06.004.
Coupland, C. A. C., Hill, T., Dening, T., Morriss, R., Moore, M., & Hippisley-Cox, J. (2019). Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study. JAMA Internal Medicine, 179(8), 1084-1093. https://doi.org/10.1001/jamainternmed.2019.0677.
Fick, D. M., Cooper, J. W., Wade, W. E., Waller, J. L., Maclean, J. R., & Beers, M. H. (2003). Updating the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults: results of a US consensus panel of experts. Archives of Internal Medicine, 163(22), 2716-2724. https://doi.org/10.1001/archinte.163.22.271.
Gallagher, P., & O’Mahony, D. (2008). STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria. Age and Ageing, 37(6), 673–679. https://doi.org/10.1093/ageing/afn19.
Ghossein, N., Kang, M., & Lakhkar, A. D. (2023). Anticholinergic medications. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK555893/.
Gray, S. L., Anderson, M. L., Hanlon, J. T., Dublin, S., Walker, R. L., Hubbard, R. A., Yu, O., Montine, T. J., Crane, P. K., Sonnen, J. A., Keene, C. D., & Larson, E. B. (2018). Exposure to Strong Anticholinergic Medications and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort. Journal of Alzheimer’s Disease: JAD, 65(2), 607–616. https://doi.org/10.3233/JAD-171174.
Gray, S. L., & Hanlon, J. T. (2016). Anticholinergic medication use and dementia: latest evidence and clinical implications. Therapeutic Advances in Drug Safety, 7(5), 217–224.https://doi.org/10.1177/204209861665839.
Grossi, C. M., Richardson, K., Fox, C., Maidment, I., Steel, N., Loke, Y. K., Arthur, A., Myint, P. K., Campbell, N., Boustani, M., Robinson, L., Brayne, C., Matthews, F. E., & Savva, G. M. (2019). Anticholinergic and benzodiazepine medication use and risk of incident dementia: a UK cohort study. BMC Geriatrics, 19(1), 276. https://doi.org/10.1186/s12877-019-1280-2.
Heath, L., Gray, S. L., Boudreau, D. M., Thummel, K., Edwards, K. L., Fullerton, S. M., Crane, P. K., & Larson, E. B. (2018). Cumulative Antidepressant Use and Risk of Dementia in a Prospective Cohort Study. Journal of the American Geriatrics Society, 66(10), 1948–1955. https://doi.org/10.1111/jgs.15508.
Joung, K. I., Kim, S., Cho, Y. H., Cho, S. I. (2019). Association of Anticholinergic Use with Incidence of Alzheimer's Disease: Population-based Cohort Study. Sci Rep, 9(1), 6802. https://doi.org/10.1038/s41598-019-43066-0.
Kumar A., Sidhu J., Lui F & Tsao. J.W. Alzheimer Disease (2024). StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https://pubmed.ncbi.nlm.nih.gov/29763097/.
Marzoughi, S., Banerjee, A., Jutzeler, C. R., Prado, M. A. M., Rosner, J., Cragg, J. J., & Cashman, N. (2021). Tardive neurotoxicity of anticholinergic drugs: A review. Journal of Neurochemistry, 158(6), 1334–1344. https://doi.org/10.1111/jnc.15244.
Peters, M. D. J., Marnie, C., Tricco, A. C., Pollock, D., Munn, Z., Alexander, L., McInerney, P., Godfrey, C. M., & Khalil, H. (2020). Updated methodological guidance for the conduct of scoping reviews. JBI evidence synthesis, 18(10), 2119–2126. https://doi.org/10.11124/JBIES-20-00167.
Poonawalla, I. B., Xu, Y., Gaddy, R. R., James, A., Karim, M., Burns, S., Dixon, S., & Suehs, B. T. (2023). Anticholinergic exposure and its association with dementia/Alzheimer’s disease and mortality in older adults. BMC Geriatrics, 23, 401. https://doi.org/10.1186/s12877-023-04095-7.
Reiter, L., Stenberg-Nilsen, H., & Økland, H. G. (2021). Use of anticholinergic drugs in older patients. Tidsskrift for Den Norske Legeforening, 141 (6), https://doi.org/10.4045/tidsskr.20.0775.
Richardson, K., Fox, C., Maidment, I., Steel, N., Loke, Y. K., Arthur, A., Myint, P. K., Grossi, C. M., Mattishent, K., Bennett, K., Campbell, N. L., Boustani, M., Robinson, L., Brayne, C., Matthews, F. E., & Savva, G. M. (2018). Anticholinergic drugs and risk of dementia: case-control study. BMJ (Clinical Research Ed.), 361(361), k1315. https://doi.org/10.1136/bmj.k1315.
Smid, J., Studart-Neto, A., César-Freitas, K. G., Dourado, M. C. N., Kochhann, R., Barbosa, B. J. A. P., Schilling, L. P., Balthazar, M. L. F., Frota, N. A. F., Souza, L. C. de, Caramelli, P., Bertolucci, P. H. F., Chaves, M. L. F., Brucki, S. M. D., Nitrini, R., Resende, E. de P. F., & Vale, F. A. C. (2022). Declínio cognitivo subjetivo, comprometimento cognitivo leve e demência - diagnóstico sindrômico: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. Dement. neuropsychol., [S. l.], v. 16, p. 1-17.
https://doi.org/10.1590/1980-5764-DN-2022-S101PT .
Tricco, A. C., Lillie, E., Zarin, W., O'Brien, K. K., Colquhoun, H., Levac, D., Moher, D., Peters, M. D. J., Horsley, T., Weeks, L., Hempel, S., Akl, E. A., Chang, C., McGowan, J., Stewart, L., Hartling, L., Aldcroft, A., Wilson, M. G., Garritty, C., Lewin, S., & Straus, S. E. (2018). PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Annals of internal medicine, 169(7), 467–473. https://doi.org/1010.7326/M18-0850.
Uusvaara, J., Pitkala, K. H., Kautiainen, H., Tilvis, R. S., & Strandberg, T. E. (2013). Detailed Cognitive Function and Use of Drugs with Anticholinergic Properties in Older People. Drugs & Aging, 30(3), 177–182. https://doi.org/10.1007/s40266-013-0055-2.
Zheng, Y.-B., Shi, L., Zhu, X.-M., Bao, Y.-P., Bai, L.-J., Li, J.-Q., Liu, J.-J., Han, Y., Shi, J., & Lu, L. (2021). Anticholinergic drugs and the risk of dementia: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews, 127, 296–306. https://doi.org/10.1016/j.neubiorev.2021.04.031.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Vitória Miranda Vilela; Tamiris Gmieski Ferraz ; Gabriel Julião de Souza; Mariana Jungles Polato; Alexandra I. S. Czepula
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
